Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of “Hold” by Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $62.1667.

SUPN has been the topic of a number of research analyst reports. Stifel Nicolaus upped their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Finally, Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $50.79 on Friday. The company has a market capitalization of $2.92 billion, a PE ratio of -74.69, a price-to-earnings-growth ratio of 1.56 and a beta of 0.70. Supernus Pharmaceuticals has a 52-week low of $29.16 and a 52-week high of $59.68. The business’s fifty day moving average is $51.00 and its 200 day moving average is $49.32.

Insider Activity

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 4,475 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $51.01, for a total transaction of $228,269.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Frederick M. Hudson sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $50.61, for a total value of $271,725.09. Following the sale, the director directly owned 60,413 shares of the company’s stock, valued at approximately $3,057,501.93. This trade represents a 8.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 120,881 shares of company stock worth $6,139,356. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently modified their holdings of SUPN. Rockefeller Capital Management L.P. lifted its stake in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares during the last quarter. Corient Private Wealth LLC bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $237,000. Sit Investment Associates Inc. grew its stake in shares of Supernus Pharmaceuticals by 0.4% during the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after buying an additional 250 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Supernus Pharmaceuticals by 9.4% in the fourth quarter. Invesco Ltd. now owns 395,761 shares of the specialty pharmaceutical company’s stock worth $19,669,000 after buying an additional 33,895 shares during the period. Finally, Mackenzie Financial Corp purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $223,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.